Elenestinib

Elenestinib (BLU-263) is Blueprint Medicines' next-generation selective KIT D816V inhibitor for indolent and smoldering systemic mastocytosis, currently in the Phase 2/3 HARBOR trial [1]. The compound is designed for minimal blood-brain barrier penetration relative to Blueprint's already-approved Ayvakit (avapritinib), aiming to give patients with milder disease a cleaner tolerability profile. Sanofi announced its acquisition of Blueprint in June 2025 (closed July 2025), putting big-pharma resources behind the program [2].

Elenestinib is a novel compound, not approved anywhere. HARBOR (NCT04910685) is a Phase 2/3 placebo-controlled study currently recruiting with a target of 534 patients [1]. A Phase 1 healthy-volunteer PK study (NCT07388511) has completed [3]. No breakthrough therapy designation has been publicly disclosed for elenestinib specifically, though orphan-eligible status is plausible given the rare-disease indication (not confirmed in FDA orphan designation searches accessed for this writeup). Blueprint originally guided that HARBOR would support a potential registration in indolent SM, but timing has not been reaffirmed publicly since Sanofi's acquisition closed in July 2025 [2]. Given that Ayvakit (avapritinib) is already approved for indolent SM based on the PIONEER trial [4], elenestinib's regulatory path leans on a differentiated safety and tolerability profile rather than superior raw efficacy. Sanofi's post-close positioning of the asset, second-in-class within its own family rather than versus a competitor drug, will shape how aggressively HARBOR is completed and read out. Competitive pressure has also intensified: Cogent Biosciences' bezuclastinib reported positive top-line SUMMIT Phase 2/3 results in non-advanced SM in 2025 and has since submitted an NDA, meaning a third KIT D816V inhibitor could reach the US market before HARBOR reads out [8].

Mast cells are immune cells that release histamine during allergic reactions. In systemic mastocytosis they proliferate out of control, causing flushing, itching, GI symptoms, bone pain, and in some patients anaphylaxis. The trigger is a single point mutation in the KIT gene, D816V, that flips the KIT receptor into a permanently on state. KIT normally sits on the mast cell surface waiting for its ligand, stem cell factor, to tell the cell to grow. The D816V mutation removes that requirement so the cell receives a nonstop growth signal. Roughly 90 percent of systemic mastocytosis cases carry this mutation [4]. Elenestinib blocks the mutant KIT kinase (biochemical IC50 approximately 6 nM against KIT D816V) and shuts down the signal [7]. The mechanism is well validated: Blueprint's own avapritinib (Ayvakit) hits the same D816V-mutant KIT and is FDA-approved for advanced systemic mastocytosis (2021) and indolent systemic mastocytosis (2023) based on the PIONEER trial [5]. Midostaurin (Rydapt) also has activity against KIT and is approved for advanced SM, though as a broader multi-kinase inhibitor. The differentiator for elenestinib is peripheral selectivity. It was engineered to minimally penetrate the blood-brain barrier, which should reduce the cognitive effects, cerebral edema, and intracranial bleeding risks that showed up in the avapritinib program and constrained its label in milder disease [7]. Mechanistically, CNS sparing is typically achieved through some combination of high P-glycoprotein efflux at the blood-brain barrier, higher polar surface area, or physicochemical properties (molecular weight, hydrogen-bond donor count) that limit passive brain penetration. Blueprint has publicly described elenestinib as having minimal CNS exposure but has not disclosed the specific chemistry feature responsible; the peripheral-restriction bet is chemistry-driven, not mechanism-driven, so it should work if the compound's tissue distribution matches preclinical predictions.

HARBOR (NCT04910685) is a two-part Phase 2/3 randomized, placebo-controlled study in indolent systemic mastocytosis, sponsored by Blueprint Medicines and now under Sanofi ownership [1]. Part 1 is a Phase 2 dose-finding portion whose registered primary endpoint is treatment-emergent adverse events. Part 2 moves into the Phase 3 comparison of elenestinib plus best supportive care versus placebo plus best supportive care. Total enrollment target is 534 patients. Efficacy readouts will lean on total symptom score reductions and objective mast cell burden markers, serum tryptase, KIT D816V allele burden in blood (allele burden meaning the fraction of DNA copies in a blood sample carrying the mutant KIT gene, a direct proxy for tumor cell load), and bone marrow mast cell percentage, the same endpoint stack Blueprint used successfully in the PIONEER trial for Ayvakit. The implicit success bar is set by PIONEER. That trial's primary endpoint was mean change in total symptom score (TSS, a patient-reported instrument scored 0 to 110) from baseline at 24 weeks. Avapritinib produced a mean TSS change of roughly minus 15.6 points versus roughly minus 9.2 points for placebo, p equals 0.003, alongside meaningful reductions in serum tryptase, KIT D816V allele burden, and bone marrow mast cell burden [7]. That approximately 6-point placebo-adjusted TSS delta is the number HARBOR needs to at least match to justify its existence. The placebo-controlled design is defensible for the indication. Indolent SM is chronic and symptom-driven, best supportive care with antihistamines and mast cell stabilizers does not modify disease, and there is no established active comparator in ISM outside of avapritinib itself, which Blueprint could not credibly run head-to-head against its next-gen candidate. The main design concern is the success bar: elenestinib's commercial rationale rests on a tolerability advantage over Ayvakit, but HARBOR is not powered against Ayvakit. Any tolerability claim will rest on cross-trial comparison to PIONEER, which regulators and payers accept only cautiously.

Our model estimates a 7% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 21%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual and larger-than-typical enrollment for this phase; it is held back by heavier-than-usual blinding and the sponsor's thin or weak approval record. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk: the peripheral-restriction chemistry that keeps elenestinib out of the CNS could also reduce drug reaching bone marrow mast cell reservoirs. If mast cell burden markers move less than they did in PIONEER (minus 15.6 vs minus 9.2 TSS at 24 weeks in avapritinib versus placebo), the tolerability pitch weakens because reviewers will ask why patients should switch from a more effective drug for a marginal AE benefit. Safety risk: on-target KIT inhibition suppresses hematopoiesis (the production of red cells, white cells, and platelets in bone marrow). Neutropenia, edema, and cognitive effects turned up in avapritinib trials [5]. The CNS-sparing design should help cognitive AEs, but the hematologic toxicity is intrinsic to KIT blockade and cannot be fully engineered out. Execution risk: HARBOR is a large placebo-controlled ISM trial in a rare disease. Enrollment competes directly with commercial Ayvakit uptake since its 2023 ISM approval. Patients doing well on Ayvakit have limited reason to enroll on a placebo-controlled trial of a competing drug from the same sponsor. Commercial risk: the sharpest one. Even with a clean HARBOR readout, Sanofi has to price and position elenestinib without cannibalizing Blueprint's roughly 500 million dollar Ayvakit franchise [6]. Payer coverage will hinge on whether elenestinib is meaningfully better tolerated, not merely non-inferior. Bezuclastinib from Cogent Biosciences (SUMMIT Phase 2/3 trial in non-advanced SM reported positive top-line data in 2025 and has since progressed to NDA submission for the non-advanced SM indication) is a real threat to compress the ISM market before Sanofi settles its own portfolio strategy [8].

Worth watching. HARBOR was enrolling against a 534-patient target while competing with commercial Ayvakit for the same rare-disease pool. Based on trial start (2021), enrollment competition, and Sanofi's July 2025 close, a realistic Part 2 primary-completion window is late 2026 to mid-2028, with topline plausibly in 2027-2028. Sanofi has not publicly reaffirmed the timeline post-close; treat that band as uncertain rather than guided. Two data points would move this from generic follow-on to must-own asset: total symptom score improvement at least matching Ayvakit's PIONEER results (a roughly 6-point placebo-adjusted TSS delta at 24 weeks) [7], and a clean AE profile with no residual signal on cognitive effects, edema, or intracranial bleeding. Anything softer means Sanofi will position elenestinib as a niche second-line option and keep Ayvakit as the ISM franchise driver. Sanofi ownership changes the calculus. Standalone Blueprint had every incentive to push elenestinib aggressively and expand its ISM foothold. Sanofi has less incentive to disrupt an already-approved product it just paid roughly nine billion dollars to acquire [2]. The most likely outcome is a differentiated label in the subset of ISM patients where avapritinib tolerability is limiting, with elenestinib pitched as expansion rather than replacement. Market sizing context: US ISM prevalence estimates land in the range of roughly 24,000 patients (extrapolating from an approximately 32,000-patient total SM population at ~75 percent ISM), with a real-world claims dataset identifying 8,332 diagnosed ISM patients across 2015-2022 [9]. The addressable KIT-inhibitor market is smaller than the diagnosed population and shared with two other KIT D816V drugs. Check back on: Sanofi's next capital markets day for guidance on the elenestinib program, and any 2026 or 2027 ASH (American Society of Hematology), EAACI (European Academy of Allergy and Clinical Immunology), or AAAAI (American Academy of Allergy, Asthma and Immunology) abstracts with HARBOR interim data on symptom scores and biomarker responses.